GLP-1 Drugs and Muscle: What the Data Show
A 2026 systematic review and meta-analysis in the International Journal of Obesity pooled seven randomized trials on GLP-1 receptor agonists used at obesity-management doses. The question was simple: how much lean mass do people lose alongside the fat, and does it matter. The answer is more nuanced than a single number can capture.
Lean mass drops, but fat drops faster
Across 821 patients, the pooled result showed an average lean mass loss of 1.74 kg compared with placebo (95% CI: -3.04 to -0.45). Semaglutide showed the largest absolute drop, at -5.44 kg (95% CI: -7.07 to -3.81). As a share of body weight, lean mass fell by 3.06% overall, with semaglutide again the steepest at -9.9%.
Those numbers sound like cause for concern on their own. But the same analysis found that lean mass as a proportion of total body weight actually rose by 1.81% (95% CI: 1.1 to 2.52). In plain terms: people lost muscle in absolute kilograms, but they lost fat faster, so the ratio of muscle to total body mass improved.
The researchers flagged very high heterogeneity in the absolute lean-mass result (I² = 98%), meaning the pooled figure blends trials that differ a lot by drug and by how long people stayed on it. A single average number hides real variation between medications.
Duration changes the picture
Time on treatment mattered more than any other factor the review could isolate. For liraglutide, lean mass loss in percentage terms grew from roughly 1% in trials under 52 weeks to more than 4% in trials that ran longer. Shorter studies likely understate what happens with sustained use.
This is a reminder that a single before-and-after comparison, taken at an arbitrary point, can miss the trend entirely. The direction of change over months is more informative than any one snapshot, and the study's own duration-dependent findings make that point directly.
None of this is a reason to start, stop, or adjust a GLP-1 medication based on a blog post. Decisions about these drugs belong with a physician who can weigh the full clinical picture, including this kind of body-composition data.
What this looks like on your own scan history
If lean mass and fat mass are both shifting, and often in different directions, a single measurement cannot tell you what is actually happening. A trend can. Tracking waist, arm circumference, and estimated body-fat percentage over consecutive scans is the practical way to see whether the ratio described in this research is showing up in your own numbers, rather than guessing from the mirror or the scale.
Trainr builds a 3D body scan from two phone photos and logs those measurements over time, so a widening or narrowing waist and a rising or falling body-fat estimate become visible trends instead of isolated data points. Remember that body-composition estimates from any consumer tool, including this one, are estimates, not lab-grade diagnostics. The first scan is free, and the value grows with each one that follows it.
Scan yourself — the first one is freeLosing some muscle and losing fat faster are not the same story, and only a trend line can tell you which one you are actually living.
Trainr is a wellness tool, not a medical device. Measurements and body-composition figures are estimates for self-tracking; for medical questions, talk to a professional.